• 1
    Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol 1987; 18: 15361.
  • 2
    Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82: 16574.
  • 3
    Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EG, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 33742.
  • 4
    Venkateswarlu D. Structural investigation of zymogenic and activated forms of human blood coagulation factor VIII: a computational molecular dynamics study. BMC Struct Biol 2010; 10: 7.
  • 5
    Collins PW, Hirsch S, Baglin TP, Dolan G, Hanley J, Makris M, Keeling DM, Liesner R, Brown SA, Hay CR. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors’ Organisation. Blood 2007; 109: 18707.
  • 6
    Huth-Kuhne A, Baudo F, Collins P, Ingerslev J, Kessler CM, Levesque H, Castellano ME, Shima M, St-Louis J. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A. Haematologica 2009; 94: 56675.
  • 7
    Franchini M, Targher G, Montagnana M, Lippi G. Laboratory, clinical and therapeutic aspects of acquired hemophilia A. Clin Chim Acta 2008; 395: 148.
  • 8
    Shetty S, Bhave M, Ghosh K. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options. Autoimmun Rev 2011; 10: 3116.
  • 9
    Franchini M, Gandini G, Di Paolantonio T, Mariani G. Acquired hemophilia A: a concise review. Am J Hematol 2005; 80: 5563.
  • 10
    Knoebl P, Marco P, Baudo F, Collins P, Huth-Kuhne A, Nemes L, Pellegrini F, Tengborn L, Levesque H. Demographic and clinical data in acquired hemophilia a: results from the european acquired haemophilia (each2) registry. J Thromb Haemost 2012; 10: 62231.
  • 11
    Kashyap R, Choudhry VP, Mahapatra M, Chumber S, Saxena R, Kaul HL. Postpartum acquired haemophilia: clinical recognition and management. Haemophilia 2001; 7: 32730.
  • 12
    Franchini M. Postpartum acquired factor VIII inhibitors. Am J Hematol 2006; 81: 76873.
  • 13
    Coller BS, Hultin MB, Hoyer LW, Miller F, Dobbs JV, Dosik MH, Berger ER. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: with observations on pathogenesis and prognosis. Blood 1981; 58: 61924.
  • 14
    Solymoss S. Postpartum acquired factor VIII inhibitors: results of a survey. Am J Hematol 1998; 59: 14.
  • 15
    Michiels JJ, Bosch LJ, van der Plas PM, Abels J. Factor VIII inhibitor postpartum. Scand J Haematol 1978; 20: 97107.
  • 16
    Hauser I, Schneider B, Lechner K. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb Haemost 1995; 73: 15.
  • 17
    Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, van Eys J, Fratantoni J, Green D, Hampton J, Hilgartner M, Levine P, Lazerson J, McMillan C, Penner J, Shapiro S, Shulman NR. Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 612.
  • 18
    Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2009; 16: 204.
  • 19
    Ma AD, Carrizosa D. Acquired factor VIII inhibitors: pathophysiology and treatment. Hematology Am Soc Hematol Educ Program 2006; 1: 4327.
  • 20
    Dazzi F, Tison T, Vianello F, Radossi P, Zerbinati P, Carraro P, Poletti A, Girolami A. High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII. Br J Haematol 1996; 93: 68893.
  • 21
    Lebreton A, Lapalud P, Chambost H, Biron-Andreani C, Morange PE, Combescure C, Marques-Verdier A, Berger C, Schved JF, Granier C, Lavigne-Lissalde G. Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. Thromb Haemost 2011; 105: 95461.
  • 22
    Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88: 56875.
  • 23
    Reding MT. Immunological aspects of inhibitor development. Haemophilia 2006; 12(Suppl 6): 305; discussion 5–6.
  • 24
    Matsumoto T, Shima M, Fukuda K, Nogami K, Giddings JC, Murakami T, Tanaka I, Yoshioka A. Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease. Thromb Res 2001; 104: 3818.
  • 25
    Lavigne-Lissalde G, Tarrade C, Lapalud P, Chtourou S, Schved JF, Granier C, Villard-Saussine S. Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 2008; 99: 10906.
  • 26
    Borg JY, Lévesque H, for the SACHA study group. Epidemiology and one-year outcomes in patients with acquired hemophilia in France. The SACHA prospective project. J Thromb Haemost 2007; 5: O-M-062.
  • 27
    Fay PJ, Haidaris PJ, Smudzin TM. Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 895762.
  • 28
    Raut S, Villard S, Grailly S, Gilles JG, Granier C, Saint-Remy JM, Barrowcliffe TW. Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor. Thromb Haemost 2003; 90: 38597.
  • 29
    Lavigne-Lissalde G, Lacroix-Desmazes S, Wootla B, Tarrade C, Schved JF, Kaveri SV, Granier C, Villard-Saussine S. Molecular characterization of human B domain-specific anti-factor VIII monoclonal antibodies generated in transgenic mice. Thromb Haemost 2007; 98: 13847.
  • 30
    Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A 1985; 82: 772832.
  • 31
    Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 161826.
  • 32
    Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 1997; 89: 366371.
  • 33
    Kopecky EM, Greinstetter S, Pabinger I, Buchacher A, Romisch J, Jungbauer A. Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. J Immunol Methods 2006; 308: 90100.
  • 34
    Gharagozlou S, Sharifian RA, Khoshnoodi J, Karimi K, Milani M, Okita DK, Shokri F, Conti-Fine BM. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Thromb Haemost 2009; 101: 8349.
  • 35
    Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res 1984; 150: 7385.
  • 36
    Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 147580.
  • 37
    Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin Hematol 1994; 31: 15.
  • 38
    van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, Mauser-Bunschoten EP, Aalberse RC, Vidarsson G, Voorberg J. IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol 2008; 142: 64452.
  • 39
    Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost 1981; 45: 2003.
  • 40
    Bossi P, Cabane J, Ninet J, Dhote R, Hanslik T, Chosidow O, Jouan-Flahault C, Horellou MH, Leynadier F, Liozon E, Pouchot J, Robin JP, Sanderson F, Schaeffer A, Sicard D, Staikowsky F, Wechsler B, Zittoun R. Acquired hemophilia due to factor VIII inhibitors in 34 patients. Am J Med 1998; 105: 4008.
  • 41
    Yee TT, Pasi KJ, Lilley PA, Lee CA. Factor VIII inhibitors in haemophiliacs: a single-centre experience over 34 years, 1964-97. Br J Haematol 1999; 104: 90914.
  • 42
    Baudo F, de Cataldo F. Acquired factor VIII inhibitors in pregnancy: data from the Italian Haemophilia Register relevant to clinical practice. BJOG 2003; 110: 3114.
  • 43
    Franchini M. Haemostasis and pregnancy. Thromb Haemost 2006; 95: 40113.
  • 44
    Zen M, Ghirardello A, Iaccarino L, Tonon M, Campana C, Arienti S, Rampudda M, Canova M, Doria A. Hormones, immune response, and pregnancy in healthy women and SLE patients. Swiss Med Wkly 2010; 140: 187201.
  • 45
    Doria A, Ghirardello A, Iaccarino L, Zampieri S, Punzi L, Tarricone E, Ruffatti A, Sulli A, Sarzi-Puttini PC, Gambari PF, Cutolo M. Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum 2004; 51: 98995.
  • 46
    Kanik KS, Wilder RL. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy. Rheum Dis Clin North Am 2000; 26: 80523.
  • 47
    Lichiardopol C, Mota M. The thyroid and autoimmunity. Rom J Intern Med 2009; 47: 20715.
  • 48
    Singh VK, Mehrotra S, Agarwal SS. The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy. Immunol Res 1999; 20: 14761.